Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

Arrowhead Pharmaceuticals Inc ARWR shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with alpha-1 antitrypsin deficiency-associated liver disease.

Why Arrowhead Pharmaceuticals Stock Is Diving Today - Arrowhead Pharma (NASDAQ:ARWR)

Takeda Pharmaceutical

OSAKA, Japan & CAMBRIDGE, Mass. & PASADENA, Calif.--( BUSINESS WIRE )--Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). The companies also provided an outline of a Phase 3 study that was co-developed by Takeda and Arrowhead and will be conducted by Takeda. Additional SEQUOIA study results are planned to be presented at a future medical meeting and submitted for publication. Arrowhead will host a webcast call for investors today, January 9, 2023, at 8:30 a.m. ET to review the Phase 2 data. To register for the webcast, visit the Events and Presentations page under the Investors section of www.arrowheadpharma.com.

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023, at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco.

Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

Arrowhead is a strong biotech with unique and powerful attributes. The company has seen its share of recent struggles, including in share price.

Arrowhead Pharmaceuticals: Good Work In Progress

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a potential treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Fazirsiran is being developed under a collaboration and licensing agreement between Arrowhead and Takeda.

Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen's Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma plc (NASDAQ: RPRX).

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase. The development of HZN-457 is part of a global collaboration and license agreement that the Company entered in 2021 with Horizon.

Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday. The post Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease appeared first on Investor's Business Daily.

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2022 Earnings Conference Call November 28, 2022 4:30 PM ET Company Participants Vincent Anzalone - VP, IR Dr. Christopher Anzalone - President and CEO Dr. Javier San Martin - Chief Medical Officer Dr. James Hamilton - SVP, Discovery and Translational Medicine Ken Myszkowski - CFO Tracie Oliver - Chief Commercial Officer Patrick O'Brien - Chief Operating Officer & General Counsel Conference Call Participants Maury Raycroft - Jefferies Luca Issi - RBC Capital Markets Ellie Merle - UBS Joel Beatty - Robert W. Baird Edward Tenthoff - Piper Sandler Patrick Trucchio - H.C.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2022 Earnings Call Transcript

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022. The company is hosting a conference call today, November 28, 2022, at 4:30 p.m. ET to discuss the results.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022.

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results

Royalty Pharma

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Arrowhead's partner Amgen reported positive phase 2 results of olpasiran in patients with elevated Lp[a]. Efficacy of the highest doses is near the maximum with 97% absolute reduction in Lp[a] concentration.

Arrowhead Pharmaceuticals: Olpasiran's Impressive Phase 2 Data

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients with severe hypertriglyceridemia and the ongoing ARCHES-2 Phase 2 clinical study of ARO-ANG3 in patients with mixed dyslipidemia, in late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago on November 5–7, 2022. The company will

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

Arrowhead is an RNA-interference drug developer with a potentially best-in-class platform in TRiM. The company has attracted five major pharmaceutical partners in Janssen, Amgen, Takeda, GSK and Horizon Therapeutics.

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats Presenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals 2022 Wells Fargo

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

Johnson & Johnson

JNJ tends to announce big news at yearly fall conference, which might be a catalyst for partnered Arrowhead Pharmaceuticals this fall. JNJ's collaboration project with Arrowhead could be ready for Phase 3 at any time, potentially triggering future milestone payments.

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF). James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead,

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2022 Results Conference Call August 4, 2022 5:00 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO James Hamilton - SVP, Discovery and Translational Medicine Tracie Oliver - Chief Commercial Officer Patrick O'Brien - Chief Operating Officer & General Counsel Conference Call Participants Luca Issi - RBC Ted Tenthoff - Piper Sandler Ellie Merle - UBS Joel Beatty - Baird Madhu Kumar - Goldman Sachs Patrick Trucchio - HC Wainwright Keay Nakae - Chardan Mani Foroohar - SVB Securities Mayank Mamtani - B. Riley FBR Prakhar Agarwal - Cantor Operator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2022 Results - Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET to discuss the results. Conference Call and Webcast Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 888-243

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50% since making an all-time high in June 2021. The company's approach has been validated by its four licensing deals, rival Alnylam's commercial success, and Novo Nordisk's buyout of RNAi concern Dicerna in 2021.

News for Arrowhead Pharmaceuticals Stock (ARWR)